Insight2020-01-29T09:24:39+00:00
Loading...

Latest news and thought leadership

All the latest from Deallus pharmaceutical and life science industry experts

Latest White Papers

The Future of JAK Inhibitors

January 6th, 2020|Categories: White Paper|Tags: , , |

From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. Yet despite the hurdles, JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted. Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option? In this white paper, we investigate the current state of JAKs and explore their likelihood of success in the future.

Digitizing Healthcare

December 18th, 2019|Categories: White Paper|Tags: , |

Healthcare has always had a reputation of being resistant to change, but consumer demand and a rapidly evolving technology-driven world have led the digitization of healthcare to move at a frantic pace. In this white paper we explore the digitization trend currently infiltrating healthcare and delve into the implications of digital health on patients, payers, and pharma itself. We take stock of the current landscape, discuss likely future trends, and explore how strategic intelligence can help answer key questions for the healthcare industry in the face of so much digital innovation.

Let’s talk about NASH

November 5th, 2019|Categories: White Paper|Tags: , |

Several promising candidates are currently competing in a multi-billion-dollar race. NASH, or non-alcoholic steatohepatitis, affects millions of patients world-wide and by 2020 is projected to replace hepatitis C as the number one reason for liver transplantation in the United States. Multiple drug developers have taken on the challenge and a variety of different approaches are currently in the pipeline to tackle this complex, silent disease. Now all eyes are on the finish line to see who will be the first to enter this lucrative and untapped market.

Latest Videos

Deallus Keynote at Pharma CiMi.CON EU 2019

October 16th, 2019|Categories: Video|Tags: , |

Jonas gives a keynote speech that delves into the importance of strategic intelligence for pharma given today’s dynamic and disruptive marketplace. He explores how competitive and strategic intelligence are related, how to build more strategically focused engagements, and how to help decision makers realize the value in strategic partnerships with their intelligence teams.

Latest News

Gloria Kwon Joins Deallus as Senior Principal

Categories: News|

We are excited to announce that Gloria Kwon has joined our Deallus team as a Senior Principal based out of our Los Angeles office. Gloria comes to Deallus with significant experience in business strategy, product commercialization and operational excellence for pharmaceutical and biotechnology companies. Prior to joining Deallus, Gloria spent over 8 years at Navigant Consulting.

Peter Barschdorff joins Deallus as Vice President (U.S.)

Categories: News|

Deallus is pleased to announce that Peter Barschdorff is joining the organization as Vice President, leading its U.S. consulting business, with offices in Los Angeles and New York. Peter has held leadership positions in a number of management consulting organizations and has built innovative enterprise capabilities in commercial pharma.

Gene therapy through different lenses

Categories: Thought Piece|

After decades of clinical research and numerous setbacks, the promise of gene therapy is now much more than a glimmering hope on the horizon. Gene therapy is poised to revolutionize medicine as it presents the opportunity to remove or change the content of an individual’s genetic code in order to potentially treat or cure disease. We explore gene therapy from a few different lenses to give a full picture of where this innovation currently stands.

Head to head trials in elbow to elbow markets

Categories: Thought Piece|

Head to head trials are proving to be a powerful mechanism for the testing of competitive medicines. A tactic for those already on the market who are eager to expand their market share, it offers the promise of considerable commercial advantage. We explore what needs to be known about head to head trials, and how they might be put to use for products operating in a saturated, competitive market.

Deallus excited to announce Peter Hempshall as new CEO

Categories: News|

Peter is a senior executive with over fifteen years of consulting and leadership experience in the healthcare sector. Prior to Deallus, Peter worked in senior roles within companies such as Decision Resources Group, PAREXEL and IMS Consulting (now IQVIA). As a consultant, he has worked with numerous pharmaceutical and biotech companies to develop and support their market access and commercial strategies.

Latest Case Studies

Competitive Simulation Strategy

Tags: , , , |

Our client was facing a major pharma player in a highly lucrative and rare disease space. They wanted to ensure that they had a chance to analyze their competition’s launch plan and plans for targeting their own product, but they did not have the time to conduct a cross-functional, traditional workshop. They came to us to discuss their goals and assess the most strategic way forward. This case study explores this launch scenario in which we put a unique spin on the traditional competitive simulation approach for our client.

Launching for Success

Tags: , , , |

Our client was a small-to medium-sized pharmaceutical company with a limited development pipeline who was in the process of launching their first product, an orphan drug, for treating a rare disease. They were a relatively small organisation with no prior knowledge of the competitive environment and no standardised launch planning process or procedures. This case study explores how our client engaged us to help them understand their competitive landscape, streamline launch efforts across markets, and stress test and revise their launch planning strategies.

Asset Evaluation

Tags: , , , , |

Our client was a medium-sized pharma company interested in launching an antibiotic asset for treating pathogens with limited treatment options in Central and Southern Europe, as well as the Middle East. Their antibiotic was a particularly strong candidate for commercialization due to its novelty in tackling multi-resistant antibiotic pathogens and the extremely high unmet demands in the targeted regions. Our client engaged us to work with their business intelligence managers in order to evaluate the commercial value of the asset and to advise on the best strategic route to commercialization.

Upcoming events

PharmaCI Europe 2020

Sponsors at PharmaCI Europe

March 19-20, 2020
Zurich, Switzerland

Learn more
eyeforpharma Conference 2020

Gold Sponsors at EyeForPharma

April 15-16, 2020
Philadelphia, Pennsylvania

Learn more
Pharma CiMi.CON 2020

Partners at Pharma CiMi.CON EU

June 15-16, 2020
Berlin, Germany

Learn more

Register your email address to be alerted to our latest news